{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:02:17Z","timestamp":1789826537395,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ahj.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:47:18Z","timestamp":1712764038000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel\/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH)"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9849-439X","authenticated-orcid":false,"given":"Emilien C.J.","family":"Wegerif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fda\u015f","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon I.","family":"Generaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger M.","family":"van den Bor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel L.","family":"Bots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.04.001_bib0001","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.108.191171","article-title":"Atherosclerotic peripheral vascular disease symposium II: nomenclature for vascular diseases","volume":"118","author":"Hiatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.001_bib0002","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ahj.2024.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2024.04.001_bib0004","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.avsg.2021.02.025","article-title":"Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization","volume":"75","author":"Desai","year":"2021","journal-title":"Annals Vascul Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0006","first-page":"627","article-title":"Below-the-knee revascularization. Advanced techniques","volume":"50","author":"Schwarzwalder","year":"2009","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.ahj.2024.04.001_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1583\/13-4625R.1","article-title":"German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization","volume":"21","author":"Krankenberg","year":"2014","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.ahj.2024.04.001_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"Editor's Choice\u20142017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3 suppl","key":"10.1016\/j.ahj.2024.04.001_bib0009","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0010","doi-asserted-by":"crossref","first-page":"Np1","DOI":"10.1177\/1358863X17701592","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary","volume":"22","author":"Gerhard-Herman","year":"2017","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0011","series-title":"Perifeer arterieel vaatlijden (PAV)","year":"2016"},{"key":"10.1016\/j.ahj.2024.04.001_bib0012","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2024.04.001_bib0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.001_bib0015","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2024.04.001_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0017","first-page":"59","article-title":"Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview","volume":"62","author":"Ipema","year":"2021","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.ahj.2024.04.001_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor's choice\u2014European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0019","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40265-022-01756-6","article-title":"Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic review and network meta-analysis","volume":"82","author":"Willems","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2024.04.001_bib0020","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"suppl S","key":"10.1016\/j.ahj.2024.04.001_bib0021","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0022","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","volume":"2012","author":"Robertson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ahj.2024.04.001_bib0023","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.001_bib0024","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0025","article-title":"Revision Dutch guideline cardiovascular disease prevention 2019","volume":"163","author":"Tjin","year":"2019","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.ahj.2024.04.001_bib0026","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11136-011-0060-z","article-title":"Validation of the Dutch version of the VascuQol questionnaire and the Amsterdam Linear Disability Score in patients with intermittent claudication","volume":"21","author":"Frans","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ahj.2024.04.001_bib0027","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/JCN.0000000000000488","article-title":"Validation of the 5-Item Medication Adherence Report Scale in older stroke patients in Iran","volume":"33","author":"Lin","year":"2018","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.ahj.2024.04.001_bib0028","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2217\/cer-2017-0029","article-title":"Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication","volume":"7","author":"Vaidya","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ahj.2024.04.001_bib0029","series-title":"Manual iMTA medical cost questionnaire (iMCQ) [in dutch: handleiding iMTA medical cost questionnaire (iMCQ)]","author":"Bouwmans","year":"2013"},{"key":"10.1016\/j.ahj.2024.04.001_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","article-title":"The iMTA Productivity Cost Questionnaire: a standardized instrument for measuring and valuing health-related productivity losses","volume":"18","author":"Bouwmans","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.ahj.2024.04.001_bib0031","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s12350-015-0209-1","volume":"22","author":"Hicks","year":"2015","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0032","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.001_bib0034","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.04.001_bib0035","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/eurheartj\/ehv584","article-title":"Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication","volume":"37","author":"Kikkert","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.001_bib0036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.04.001_bib0037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.avsg.2020.05.040","article-title":"The Reintervention Index: a new outcome measure for comparative effectiveness of lower extremity revascularization","volume":"69","author":"Ochoa Chaar","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a paclitaxel-coated balloon for femoropopliteal artery disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0039","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ejvs.2019.06.012","article-title":"Interwoven nitinol stents versus drug eluting stents in the femoro-popliteal segment: a propensity matched analysis","volume":"58","author":"Saratzis","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1024\/0301-1526\/a000798","article-title":"Real-world outcomes of endovascular treatment in a non-selected population with peripheral artery disease\u2014prospective study with 2-year follow-up","volume":"48","author":"Schulte","year":"2019","journal-title":"Vasa"},{"key":"10.1016\/j.ahj.2024.04.001_bib0041","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","article-title":"Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","volume":"199","author":"Capell","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.04.001_bib0042","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.109.904003","article-title":"Medication adherence in cardiovascular disease","volume":"121","author":"Baroletti","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.001_bib0043","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.amjcard.2019.03.022","article-title":"Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease","volume":"123","author":"Berger","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0044","series-title":"Beoordeling stand van de wetenschap en praktijk","author":"Nederland","year":"2015"},{"key":"10.1016\/j.ahj.2024.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Intervent"},{"key":"10.1016\/j.ahj.2024.04.001_bib0046","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ijcard.2012.05.100","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis","volume":"167","author":"Aradi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0047","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0048","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2024.04.001_bib0049","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.001_bib0050","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jvs.2017.07.065","article-title":"Review of aspirin and clopidogrel resistance in peripheral arterial disease","volume":"66","author":"Guirgis","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0051","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","author":"Leunissen","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0052","unstructured":"KNMP Kennisbank. Antitrombotica. 2022;3:1-29. Retrieved from: https:\/\/kennisbank.knmp.nl\/."},{"key":"10.1016\/j.ahj.2024.04.001_bib0053","unstructured":"E De Jongh, NJ De Wit, ME Numans, et al., Preventie van maagcomplicaties door geneesmiddelgebruik, 2021, Nederlands Huisartsen Genootschap (NHG)-Richtlijnen. Retrieved from: Preventie van maagcomplicaties door geneesmiddelgebruik | NHG-Richtlijnen."},{"key":"10.1016\/j.ahj.2024.04.001_bib0054","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijcp.12634","article-title":"Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis","volume":"69","author":"Tran-Duy","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2024.04.001_bib0055","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.001_bib0056","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2024.04.001_bib0057","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1583\/13-4275MR.1","article-title":"Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease","volume":"20","author":"Strobl","year":"2013","journal-title":"J Endovasc Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T02:36:41Z","timestamp":1721356601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"alternative-id":["S0002870324000802"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.04.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel\/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}